1-[苯基-[4-(三氟甲基)苯基]甲基]哌嗪 | 1536-18-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[苯基-[4-(三氟甲基)苯基]甲基]哌嗪
• 英文名称: 1-[(4-trifluoromethylphenyl)phenylmethyl]piperazine
• 英文别名: 4-(4-trifluoromethylbenzhydryl)piperazine；1-(4-trifluoromethyl-benzhydryl)-piperazine；1-[phenyl-(4-trifluoromethylphenyl)methyl]piperazine dichloride；1-(phenyl(4-(trifluoromethyl)phenyl)methyl)piperazine；1-<4-Trifluormethyl-benzhydryl>-piperazin；1-[Phenyl-[4-(trifluoromethyl)phenyl]methyl]piperazine
• CAS: 1536-18-1
• 化学式: C₁₈H₁₉F₃N₂
• 分子量: 320.357
• InChiKey: HLMJOIZGABPANJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-氯-1-苯基-1H-吡唑并[3,4-d]嘧啶 、 1-[苯基-[4-(三氟甲基)苯基]甲基]哌嗪 在 三乙胺 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 1-phenyl-4-(4-phenyl[4-(trifluoromethyl)phenyl]methylpiperazino)-1H-pyrazolo[3,4-d]pyrimidine
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of pyrazolo[3,4-d]pyrimidines: a novel class of potent enterovirus inhibitors

  摘要：

  A series of pyrazolo[3,4-d]pyrimidines were synthesized. and their antiviral activity was evaluated in a plaque reduction assay. It is very interesting that this class of compounds provide remarkable evidence that they are very specific for human enteroviruses, in particular, coxsackieviruses. Some derivatives proved to be highly effective in inhibiting enterovirus replication at nanomolar concentrations. SAR studies revealed that the phenyl group at the N-I position and the hydrophobic diarylmethyl group at the piperazine largely influenced the in vitro antienteroviral activity of this new class of potent antiviral agents. It was found that the pyrazolo[3,4-d]pyrimidines with a thiophene substituent, such as compounds 20 24, in general exhibited high activity against coxsackievirus B3 (IC50 = 0.063-0.089 muM) and moderate activity against enterovirus 71 (IC50 = 0.32-0.65 muM) with no apparent cytotoxic effect toward RD (rhabdomyosarcoma) cell lines (CC50>25 muM). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.092
• 作为产物：
  描述：

  4-三氟甲基-二苯甲醇 在 氯化亚砜 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 1.0h， 生成 1-[苯基-[4-(三氟甲基)苯基]甲基]哌嗪
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of pyrazolo[3,4-d]pyrimidines: a novel class of potent enterovirus inhibitors

  摘要：

  A series of pyrazolo[3,4-d]pyrimidines were synthesized. and their antiviral activity was evaluated in a plaque reduction assay. It is very interesting that this class of compounds provide remarkable evidence that they are very specific for human enteroviruses, in particular, coxsackieviruses. Some derivatives proved to be highly effective in inhibiting enterovirus replication at nanomolar concentrations. SAR studies revealed that the phenyl group at the N-I position and the hydrophobic diarylmethyl group at the piperazine largely influenced the in vitro antienteroviral activity of this new class of potent antiviral agents. It was found that the pyrazolo[3,4-d]pyrimidines with a thiophene substituent, such as compounds 20 24, in general exhibited high activity against coxsackievirus B3 (IC50 = 0.063-0.089 muM) and moderate activity against enterovirus 71 (IC50 = 0.32-0.65 muM) with no apparent cytotoxic effect toward RD (rhabdomyosarcoma) cell lines (CC50>25 muM). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.092

文献信息

• [EN] BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS<br/>[FR] DÉRIVÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'AFFECTIONS ASSOCIÉES AU RÉCEPTEUR DES ANDROGÈNES
  申请人：ASTRAZENECA AB

  公开号：WO2009081197A1

  公开（公告）日：2009-07-02

  The invention concerns bicyclic compounds of Formula (I), wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.

  该发明涉及式(I)的双环化合物，其中整数X1、X2、X3、环A、R4、R5和m的定义如描述中所示。本发明还涉及制备这些化合物的方法、含有它们的药物组合物以及它们在制备用于预防或治疗雄激素受体相关疾病的药物中的应用。
• Glycine transporter-1 inhibitors
  申请人：Hitchcock Stephen

  公开号：US20080004289A1

  公开（公告）日：2008-01-03

  The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了一种甘氨酸转运蛋白1（以下简称为GlyT-1）抑制剂的化合物，因此可用于治疗通过抑制GlyT1可治疗的疾病，如与精神分裂症、注意力缺陷多动障碍（ADHD）、轻度认知障碍（MCI）等相关的认知障碍。还提供了含有这种化合物的药物组合物以及制备这种化合物的方法。
• [EN] PROCESS FOR THE PREPARATION OF ROSUVASTATIN<br/>[FR] PROCÉDÉ DE PRÉPARATION DE ROSUVASTATINE
  申请人：KRKA TOVARNA ZDRAVIL D D NOVO

  公开号：WO2010081861A1

  公开（公告）日：2010-07-22

  The invention relates to a process for the preparation of a HMG - CoA reductase inhibitor such as rosuvastatin, as well as intermediates useful in such process. The invention also relates to salts of HMG-CoA reductase inhibitors and processes for preparing same as well as processes for preparing pharmaceutically acceptable salts of HMG-CoA reductase inhibitors.

  该发明涉及一种用于制备类似罗伐他汀的HMG - CoA还原酶抑制剂的过程，以及在该过程中有用的中间体。该发明还涉及HMG-CoA还原酶抑制剂的盐以及制备其的过程，以及制备HMG-CoA还原酶抑制剂的药用可接受盐的过程。
• [EN] PROCESSES FOR PREPARATION OF MONTELUKAST SODIUM AND PURIFICATION OF DIOL INTERMEDIATE<br/>[FR] MÉTHODES DE PRÉPARATION DE MONTÉLUKAST DE SODIUM ET DE PURIFICATION D'UN INTERMÉDIAIRE DIOL
  申请人：IND SWIFT LAB LTD

  公开号：WO2012077133A1

  公开（公告）日：2012-06-14

  A process for preparation of montelukast sodium through novel montelukast amine salts is provided, wherein the amine is selected from 1- (l-naphthyl)ethylamine, S-methyl-L-cysteine, diallylamine or isomers thereof. A process for purification of 2-(2-(3-(S)-(3-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-hydroxylpropyl)-phenyl-2-propanol is also provided, which uses a halogenated hydrocarbon and a nitrile as solvent.

  提供一种通过新颖的蒙特鲁卡斯特胺盐制备蒙特鲁卡斯特钠的方法，其中所选的胺来自1-(1-萘基)乙胺，S-甲基-L-半胱氨酸，二烯基胺或其异构体。还提供了一种用卤代烃和腈作为溶剂的纯化2-(2-(3-(S)-(3-(7-氯-2-喹啉基)-乙烯基)苯基)-3-羟基丙基)-苯基-2-丙醇的方法。
• [EN] MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF<br/>[FR] SELS DE PIPÉRAZINE DE BENZHYDRYLE DE MONTÉLUKAST ET LEUR PROCÉDÉ DE PRÉPARATION
  申请人：TORRENT PHARMACEUTICALS LTD

  公开号：WO2009113087A1

  公开（公告）日：2009-09-17

  The invention relates to Benzhydryl piperazine salts of [R-(E)] -1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl]-3-[2-(1 -hydroxy-1-methylethyl) phenyl] propyl] thio] methyl] cyclopropaneacetic acid represented by the formula (III). Furthermore, the invention relates to the use of Benzhydryl piperazine salts of [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl) phenyl] propyl] thio] methyl] cyclopropaneacetic acid represented by the formula (III) for the preparation of substantially pure [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl] -3 -[2-(1-hydroxy-1- methylethyl) phenyl] propyl] thio] methyl] cyclopropane acetic acid or its alkali, salts and pharmaceutical composition comprising the same.

  本发明涉及由式（III）表示的[R-(E)]-1-[[[1-[3-[2-(7-氯-2-喹啉基)乙烯基]苯基]-3-[2-(1-羟基-1-甲基乙基)苯基]丙基]硫]甲基]环丙烷乙酸的苯甲基哌嗪盐。此外，本发明还涉及使用由式（III）表示的苯甲基哌嗪盐[R-(E)]-1-[[[1-[3-[2-(7-氯-2-喹啉基)乙烯基]苯基]-3-[2-(1-羟基-1-甲基乙基)苯基]丙基]硫]甲基]环丙烷乙酸或其碱盐制备基本纯的[R-(E)]-1-[[[1-[3-[2-(7-氯-2-喹啉基)乙烯基]苯基]-3-[2-(1-羟基-1-甲基乙基)苯基]丙基]硫]甲基]环丙烷乙酸或其碱盐和包含它们的药物组合物的用途。